These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Biochemical and stone-risk profiles with topiramate treatment. Welch BJ; Graybeal D; Moe OW; Maalouf NM; Sakhaee K Am J Kidney Dis; 2006 Oct; 48(4):555-63. PubMed ID: 16997051 [TBL] [Abstract][Full Text] [Related]
4. Topiramate and metabolic acidosis: an evolving story. Gupta S; Gao JJ; Emmett M; Fenves AZ Hosp Pract (1995); 2017 Dec; 45(5):192-195. PubMed ID: 28828886 [TBL] [Abstract][Full Text] [Related]
5. Prevalence and spot urine risk factors for renal stones in children taking topiramate. Corbin Bush N; Twombley K; Ahn J; Oliveira C; Arnold S; Maalouf NM; Sakhaee K J Pediatr Urol; 2013 Dec; 9(6 Pt A):884-9. PubMed ID: 23375465 [TBL] [Abstract][Full Text] [Related]
6. Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review. Dell'Orto VG; Belotti EA; Goeggel-Simonetti B; Simonetti GD; Ramelli GP; Bianchetti MG; Lava SA Br J Clin Pharmacol; 2014 Jun; 77(6):958-64. PubMed ID: 24219102 [TBL] [Abstract][Full Text] [Related]
7. Patients with and without prior urolithiasis have hypocitraturia and incident kidney stones while on topiramate. Kaplon DM; Penniston KL; Nakada SY Urology; 2011 Feb; 77(2):295-8. PubMed ID: 20888032 [TBL] [Abstract][Full Text] [Related]
9. Topiramate-induced metabolic acidosis: report of two cases. Ko CH; Kong CK Dev Med Child Neurol; 2001 Oct; 43(10):701-4. PubMed ID: 11665828 [TBL] [Abstract][Full Text] [Related]
10. Chronic impact of topiramate on acid-base balance and potassium in childhood. Belotti EA; Taddeo I; Ragazzi M; Pifferini R; Simonetti GD; Bianchetti MG; Ramelli GP Eur J Paediatr Neurol; 2010 Sep; 14(5):445-8. PubMed ID: 20005754 [TBL] [Abstract][Full Text] [Related]
11. Topiramate-induced nephrolithiasis. Kuo RL; Moran ME; Kim DH; Abrahams HM; White MD; Lingeman JE J Endourol; 2002 May; 16(4):229-31. PubMed ID: 12042105 [TBL] [Abstract][Full Text] [Related]
13. Hyperventilation and cerebrospinal fluid acidosis caused by topiramate. Montcriol A; Meaudre E; Kenane N; Asencio Y; Bordes J; Palmier B Ann Pharmacother; 2008 Apr; 42(4):584-7. PubMed ID: 18420530 [TBL] [Abstract][Full Text] [Related]
14. Predisposition to metabolic acidosis induced by topiramate. Montenegro MA; Guerreiro MM; Scotoni AE; Guerreiro CA Arq Neuropsiquiatr; 2000 Dec; 58(4):1021-4. PubMed ID: 11105067 [TBL] [Abstract][Full Text] [Related]
15. The risk and management of kidney stones from the use of topiramate and zonisamide in migraine and idiopathic intracranial hypertension. Jion YI; Raff A; Grosberg BM; Evans RW Headache; 2015 Jan; 55(1):161-6. PubMed ID: 25486999 [No Abstract] [Full Text] [Related]
16. Hallucinations and comorbid renal tubular acidosis caused by topiramate in a patient with psychiatric history. Cheng M; Wen S; Tang X; Zhong Z Gen Hosp Psychiatry; 2013; 35(2):213.e1-3. PubMed ID: 22657836 [TBL] [Abstract][Full Text] [Related]
18. Severe non-anion gap metabolic acidosis induced by topiramate: a case report. Shiber JR J Emerg Med; 2010 May; 38(4):494-6. PubMed ID: 19232874 [TBL] [Abstract][Full Text] [Related]
19. [Topiramate in monotherapy or in combination as a cause of metabolic acidosis in adults with epilepsy]. Ruiz-Granados VJ; Márquez-Romero JM Rev Neurol; 2015 Feb; 60(4):159-63. PubMed ID: 25670045 [TBL] [Abstract][Full Text] [Related]
20. Acute mental status changes and hyperchloremic metabolic acidosis with long-term topiramate therapy. Stowe CD; Bollinger T; James LP; Haley TM; Griebel ML; Farrar HC Pharmacotherapy; 2000 Jan; 20(1):105-9. PubMed ID: 10641984 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]